title: Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK.
abstract: The purpose of this study was to investigate the effect of bufalin on the anti-proliferative activity of sorafenib in the human hepatocellular carcinoma (HCC) cell lines PLC/PRF/5 and Hep G-2 and to determine the relevant molecular mechanism. Concurrent treatment with sorafenib and bufalin at a fixed ratio (25:1) for 48 h resulted in synergistic growth inhibition in HCC cell lines as determined by CCK-8 cell viability assays. Exposure of both PLC/PRF/5 and Hep G-2 cells to this combination of sorafenib (6.25 μM) and bufalin (50 nM) resulted in noticeable increases in apoptotic cell death, as evidenced by the disruption of mitochondria, compared to treatment with either agent alone. Although both sorafenib (6.25 μM) and bufalin (250 nM) alone inhibited the phosphorylation of ERK, the reduction in pERK was more pronounced in the cells treated with a combination of bufalin (50 nM) and sorafenib (250 nM). Furthermore, the inhibitory effect of bufalin on pERK was blocked by the PI3kinase inhibitor LY294002, suggesting that the reduction in pERK induced by bufalin might be mediated by AKT in these two HCC cell lines. Taken together, the results of our study suggest that bufalin enhances the anti-cancer effects of sorafenib on PLC/PRF/5 and Hep G-2 by contributing to the downregulation of ERK.
authors: Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
authors: Yang
authors: Y
authors: Gao
authors: Hua-Xing
authors: HX
authors: Li
authors: Li-Tao
authors: LT
authors: Xu
authors: Peng
authors: P
authors: Wang
authors: Li-Yan
authors: LY
authors: Xu
authors: Lorenzo
authors: L
authors: Cohen
authors: Pei-Ying
authors: PY
authors: Yang
authors: Ke
authors: K
authors: Gu
authors: Zhi-Qiang
authors: ZQ
authors: Meng
references: N Engl J Med. 2008 Jul 24;359(4):378-90
references: 18650514
references: Mol Cancer Ther. 2008 Oct;7(10):3129-40
references: 18852116
references: Int J Oncol. 2009 Jun;34(6):1749-57
references: 19424594
references: Nan Fang Yi Ke Da Xue Xue Bao. 2008 Apr;28(4):639-41
references: 18495609
references: J Chromatogr Sci. 2008 Jan;46(1):81-5
references: 18218193
references: Adv Enzyme Regul. 2006;46:249-79
references: 16854453
references: Nan Fang Yi Ke Da Xue Xue Bao. 2008 Aug;28(9):1684-7
references: 18819900
references: Int J Mol Med. 2008 May;21(5):637-43
references: 18425357
references: Prostate. 2003 Feb 1;54(2):112-24
references: 12497584
references: Cancer Cell. 2008 Dec 9;14(6):427-9
references: 19061832
references: Hepatology. 2005 Nov;42(5):1208-36
references: 16250051
references: Hepatology. 2008 Dec;48(6):2047-63
references: 19003900
references: Integr Cancer Ther. 2007 Dec;6(4):354-64
references: 18048883
references: Clin Cancer Res. 2008 Aug 15;14(16):5124-30
references: 18698030
references: Lancet Oncol. 2009 Jan;10(1):25-34
references: 19095497
references: Gan. 1967 Dec;58(6):521-8
references: 5589524
references: Evid Based Complement Alternat Med. 2011;2011:249090
references: 19592481
references: J Pathol. 2007 Jun;212(2):170-9
references: 17471453
references: Ai Zheng. 2009 Aug;28(8):838-43
references: 19664330
references: Anticancer Drugs. 2009 Jan;20(1):59-64
references: 19343001
references: Mol Biol Rep. 2011 Mar;38(3):1757-67
references: 20857219
references: CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
references: 15761078
references: BMC Med. 2009 Aug 24;7:41
references: 19698189
references: Cancer Res. 2010 Jan 15;70(2):440-6
references: 20068163
references: Science. 1999 Nov 26;286(5445):1738-41
references: 10576741
references: J Hepatol. 2001 Sep;35(3):421-30
references: 11592607
references: Radiat Oncol. 2010 Feb 12;5:12
references: 20149262
references: Lancet. 2003 Dec 6;362(9399):1907-17
references: 14667750
references: Cancer Cell. 2008 Dec 9;14(6):458-70
references: 19061837